Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 MPNs Highlights
07 February 2025 | Virtual Webinar
Post-ASH 2024 MPNs Highlights
Featuring presentations & discussions on selected MPNs abstracts from the 66th ASH Annual Meeting and Exposition
Friday 7 February | 12:00 – 14:00 CST/ 18:00 – 20:00 GMT/ 19:00 – 21:00 CET
Chair: Claire Harrison | Moderators: Francesca Palandri and Naveen Pemmaraju
The Post-ASH 2024 MPNs Highlights was supported by Kartos Therapeutics and Sumitomo Pharma. Supporters have no influence over the production of content.
Explore all presentations and discussions below:
Session 1: Impact of molecular profiling on MPNs prognosis and treatment decisions
Personalized transplant decision making for myelofibrosis in the era of molecular genetics and JAK inhibition
Nico Gagelmann University Medical Center Hamburg-Eppendorf, Hamburg, Germany
TP53 alterations confer increased risk of leukemic transformation and worse survival as compared to high molecular risk mutations in patients with myeloproliferative neoplasms
Shivani Handa Ohio State University, OH, United States
Clinical relevance of the integrative analysis of gut microbiome and metabolomics in myeloid neoplasms
Alessia Campagna Humanitas University, Milan, Italy
Panel discussion
Session 2: Novel treatments & combinations for MPNs
IMproveMF trial update: Phase I/Ib study evaluating the safety and activity of imetelstat with ruxolitinib in intermediate to high-risk MF
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Updated results from the Phase III Manifest-2 study of pelabresib in combination with ruxolitinib for JAK-inhibitor naïve patients with myelofibrosis
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Efficacy and safety of fedratinib in patients with myelofibrosis and low baseline platelet counts in the Phase III randomized FREEDOM2 trial
Haifa Kathrin Al-Ali Martin Luther University of Halle-Wittenberg, Halle, Germany
Open-label study of add on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib
Lucia Masarova The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Initial results from a Phase I/II study evaluating divesiran, a novel galnac conjugated siRNA, in patients with polycythemia vera (SANRECO)
Marina Kremyanskaya Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Panel discussion
Session 3: Novel approaches for relapsed/refractory & JAKi ineligible MPNs
Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients
Firas El Chaer University of Virginia, Charlottesville, VA, United States
Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis from the ongoing Phase II Restore trial
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Updates with navtemadlin from the randomized, multicenter, global Phase III BOREAS study
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Panel discussion
Session 4: Advances in mastocytosis prognostics and management
Updated assessment of bezuclastinib (CGT9486), a selective KIT D816V tyrosine kinase inhibitor, in patients with advanced systemic mastocytosis (AdvSM)
Daniel DeAngelo Dana-Farber Cancer Institute, Boston, MA, United States
Redefining prognosis in patients with KIT D816V positive advanced systemic mastocytosis on KIT inhibitors
Johannes Lübke Heidelberg University, Heidelberg, , Germany
Panel discussion
